

Phuoc T Tran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2464892/publications.pdf>

Version: 2024-02-01

265
papers

10,006
citations

41627

51
h-index

48101

92
g-index

269
all docs

269
docs citations

269
times ranked

16059
citing authors

#	ARTICLE	IF	CITATIONS
1	Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches. <i>Journal of the National Cancer Institute</i> , 2022, 114, 139-148.	3.0	1
2	Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial. <i>Journal of Cancer Survivorship</i> , 2022, 16, 791-800.	1.5	2
3	<scp>BCG</scp> invokes superior <scp>STING</scp>-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. <i>Journal of Pathology</i> , 2022, 256, 223-234.	2.1	9
4	Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?. <i>Prostate</i> , 2022, , .	1.2	1
5	The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 339-341.	2.8	6
6	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 713-719.	2.0	17
7	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	3.4	18
8	Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. <i>Radiotherapy and Oncology</i> , 2022, 167, 226-232.	0.3	7
9	Development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 222-222.	0.8	1
10	Early initiation of salvage radiotherapy is associated with improved metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 262-262.	0.8	0
11	Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.. <i>Journal of Clinical Oncology</i> , 2022, 40, 269-269.	0.8	4
12	Patient-specific deep learning model to enhance 4D-CBCT image for radiomics analysis. <i>Physics in Medicine and Biology</i> , 2022, 67, 085003.	1.6	4
13	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 278-289.	0.4	4
14	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	1.2	6
15	Genomic biomarkers to guide precision radiotherapy in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	3
16	Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 108-108.	0.8	1
17	Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5025-5025.	0.8	3
18	Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5012-5012.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5011-5011.	0.8	2
20	A phase III double blinded study of early intervention after radical prostatectomy with androgen deprivation therapy with darolutamide versus placebo in men at highest risk of prostate cancer metastasis by genomic stratification (ERADICATE).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5114-TPS5114.	0.8	3
21	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 447-455.	2.6	52
22	Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries. <i>World Journal of Urology</i> , 2021, 39, 317-326.	1.2	18
23	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 35-52.	0.4	54
24	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 387-395.	0.4	19
25	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
26	(Oligo)metastasis as a Spectrum of Disease. <i>Cancer Research</i> , 2021, 81, 2577-2583.	0.4	22
27	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1623-1630.	3.2	33
28	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	0.9	61
29	What are survivorship care plans failing to tell men after prostate cancer treatment?. <i>Prostate</i> , 2021, 81, 398-406.	1.2	4
30	Twist1 is required for the development of UVB α -induced squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021, 60, 342-353.	1.3	9
31	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.	3.4	82
32	The hexosamine biosynthetic pathway and cancer: Current knowledge and future therapeutic strategies. <i>Cancer Letters</i> , 2021, 503, 11-18.	3.2	47
33	Abstract PO-067: The transactivation domain of TWIST1 is required for TWIST1-induced aggressiveness in non-small cell lung cancer. , 2021, , .		0
34	Abstract PO-030: The harmala alkaloid harmine as a novel cancer cell radiosensitizer. , 2021, , .		0
35	Simplifying survivorship care planning: A randomized controlled trial comparing three care plan delivery approaches.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12024-12024.	0.8	0
36	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12

#	ARTICLE	IF	CITATIONS
37	Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 242-249.	1.0	7
38	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	0.9	12
39	In Reply to Onal et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1547-1548.	0.4	0
40	Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 914-923.	2.6	23
41	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€‘Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
42	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	0.9	18
43	A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 184-193.	2.0	32
44	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	0.9	37
45	Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer. <i>Urology</i> , 2020, 135, 111-116.	0.5	0
46	Online Prostate-Specific Membrane Antigen and Positron Emission Tomographyâ€‘Guided Radiation Therapy for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 260-268.	0.6	13
47	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
48	Organotypic culture assays for murine and human primary and metastatic-site tumors. <i>Nature Protocols</i> , 2020, 15, 2413-2442.	5.5	40
49	Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 575992.	1.3	30
50	Metastasis-Directed Therapy for Oligorecurrent Prostate Cancerâ€‘Not All That Glitters Is Goldâ€‘Reply. <i>JAMA Oncology</i> , 2020, 6, 1639.	3.4	1
51	Impact of radiation dose on recurrence in highâ€‘risk prostate cancer patients. <i>Prostate</i> , 2020, 80, 1322-1327.	1.2	1
52	Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 137-143.	1.0	20
53	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
54	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.4	11

#	ARTICLE	IF	CITATIONS
55	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). BMC Cancer, 2020, 20, 492.	1.1	16
56	Radiotherapy in the Management of Metastatic Hormone-Sensitive Prostate Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 87-93.	1.0	4
57	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 650.	3.4	696
58	An Integrated Program in a Pandemic: Johns Hopkins Radiation Oncology Department. Advances in Radiation Oncology, 2020, 5, 666-672.	0.6	14
59	Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.. Journal of Clinical Oncology, 2020, 38, 276-276.	0.8	9
60	MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. ELife, 2020, 9, .	2.8	38
61	MicroRNA-based biomarkers of the radiation response in prostate cancer.. Journal of Clinical Oncology, 2020, 38, 163-163.	0.8	0
62	Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2020, 38, 211-211.	0.8	0
63	Testosterone recovery as biomarker for overall and cause-specific survival in combined treated patients with high-risk and locally advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, 188-188.	0.8	0
64	In vivo bioluminescence tomography-guided radiation research platform for pancreatic cancer: an initial study using subcutaneous and orthotopic pancreatic tumor models. , 2020, 11224, .		4
65	A phase II randomized trial of Radium-223 dichloride and SABR versus SABR for oligometastatic prostate cancer (RAVENS).. Journal of Clinical Oncology, 2020, 38, TPS5586-TPS5586.	0.8	1
66	Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer.. Journal of Clinical Oncology, 2020, 38, 208-208.	0.8	0
67	Prostate cancer survivorship care plans: What we are failing to tell men after treatment?. Journal of Clinical Oncology, 2020, 38, 311-311.	0.8	0
68	Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.. Journal of Clinical Oncology, 2020, 38, 327-327.	0.8	1
69	Predicting long-term results with circulating tumor cells in patients with de novo androgen sensitive prostate cancer treated with hTERT peptides vaccine.. Journal of Clinical Oncology, 2020, 38, 98-98.	0.8	0
70	PSA status after neoadjuvant androgen deprivation therapy before high-dose-rate brachytherapy as biomarker for prediction of long-term outcome in high-risk prostate cancer patients.. Journal of Clinical Oncology, 2020, 38, 301-301.	0.8	1
71	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate Cancer (ORIOLE).. Journal of Clinical Oncology, 2020, 38, 116-116.	0.8	1
72	Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. Npj Systems Biology and Applications, 2019, 5, 29.	1.4	17

#	ARTICLE	IF	CITATIONS
73	Developments in oligometastatic hormone-sensitive prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2545-2547.	1.2	2
74	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 948-956.	0.4	37
75	What Is Oligometastatic Prostate Cancer?. <i>European Urology Focus</i> , 2019, 5, 159-161.	1.6	24
76	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019, 19, 572.	1.1	3
77	Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations. <i>Advances in Cancer Research</i> , 2019, 142, 23-62.	1.9	12
78	Authorâ€™s view: epithelial plasticity metabolically reprograms normal cells towards a neoplastic-prone state. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1543485.	0.3	0
79	Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e313-e314.	0.7	3
80	Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. <i>Oncogene</i> , 2019, 38, 656-670.	2.6	140
81	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. <i>World Journal of Urology</i> , 2019, 37, 2623-2629.	1.2	21
82	Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 289.e19-289.e26.	0.8	4
83	Clinical Development of Novel Drugâ€™Radiotherapy Combinations. <i>Clinical Cancer Research</i> , 2019, 25, 1455-1461.	3.2	42
84	Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. <i>European Urology</i> , 2019, 76, 170-176.	0.9	71
85	Is Androgen Deprivation Therapy â€™Another Deficient Therapyâ€™ for Gleason Score 9-10 Prostate Cancer?. <i>European Urology</i> , 2019, 75, 42-43.	0.9	1
86	Adjuvant radiation with androgenâ€™deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. <i>BJU International</i> , 2019, 123, 252-260.	1.3	34
87	Cost-effectiveness of metastasis-directed therapy in the setting of oligometastatic hormone-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 147-147.	0.8	2
88	Genomic biomarkers to predict outcome in Gleason Score 9-10 disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, 44-44.	0.8	0
89	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	3.8	252
90	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	5.1	108

#	ARTICLE	IF	CITATIONS
91	Live to SABR Another Day?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1097.	0.4	0
92	Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e7-309.e14.	0.8	8
93	Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 126-136.	2.0	33
94	Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality. Prostate, 2018, 78, 623-630.	1.2	0
95	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. European Urology, 2018, 73, 156-165.	0.9	55
96	Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment. Oncogene, 2018, 37, 63-74.	2.6	58
97	Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT. Urology Case Reports, 2018, 16, 86-88.	0.1	4
98	Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al. Journal of Clinical Oncology, 2018, 36, 2352-2353.	0.8	0
99	STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 435-437.	0.8	6
100	ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. Journal of Clinical Investigation, 2018, 128, 3926-3940.	3.9	136
101	SABR Produces Systemic Adaptive Immune Responses in Castration-Sensitive Oligometastatic Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 102, S24-S25.	0.4	1
102	Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e134-e135.	0.4	2
103	Impact of Corticosteroids on the Efficacy of Anti-PD-1 Therapy for Tumors Located Within or Outside the Central Nervous System. International Journal of Radiation Oncology Biology Physics, 2018, 102, S170.	0.4	2
104	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. Oncoimmunology, 2018, 7, e1500108.	2.1	52
105	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-Institutional Consortium Study. International Journal of Radiation Oncology Biology Physics, 2018, 101, 883-888.	0.4	10
106	Data integrity systems for organ contours in radiation therapy planning. Journal of Applied Clinical Medical Physics, 2018, 19, 58-67.	0.8	3
107	Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. European Urology Oncology, 2018, 1, 3-18.	2.6	10
108	O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. Journal of Clinical Investigation, 2018, 128, 4924-4937.	3.9	51

#	ARTICLE	IF	CITATIONS
109	Clinical outcomes following biochemical recurrence among patients with Gleason score 9-10 prostate adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 102-102.	0.8	0
110	Efficacy of radium-223 in bone-metastatic prostate cancer patients with and without homologous repair deficiency (HRD) mutations.. Journal of Clinical Oncology, 2018, 36, e17023-e17023.	0.8	0
111	Abstract 3620: Histopathological associations with PTEN and ERG status in prostate biopsies from men treated with radiation. , 2018, ,		0
112	Abstract 1094: A role for olfactory-like chemosensory signaling in prostate cancer metastasis. , 2018, ,		0
113	Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clinical Cancer Research, 2017, 23, 124-136.	3.2	345
114	End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 203-209.	2.0	4
115	TWIST1-WDR5- <i>Hottip</i> Regulates <i>Hoxa9</i> Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Research, 2017, 77, 3181-3193.	0.4	102
116	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer, 2017, 123, 1912-1924.	2.0	52
117	Oligoprogression. Academic Radiology, 2017, 24, 898-900.	1.3	7
118	Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease. Prostate Cancer and Prostatic Diseases, 2017, 20, 193-196.	2.0	6
119	Changes in Radiotherapeutic Management of Prostate Cancer Following PSMA-based 18 F-DCFPyL PET Imaging: A Snapshot of Prospective Trials at a Single Institution. International Journal of Radiation Oncology Biology Physics, 2017, 99, E259-E260.	0.4	0
120	Characterizing Tumor Infiltrating Lymphocytes Following Neoadjuvant Chemotherapy and Radiation in Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, S91-S92.	0.4	1
121	What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?. Future Oncology, 2017, 13, 2121-2124.	1.1	2
122	ATR Kinase Inhibition Leads to Durable Radiosensitization of the Murine Kras G12D /Twist1 Lung Adenocarcinoma Model via a CD8 + T Cell-Dependent Mechanism. International Journal of Radiation Oncology Biology Physics, 2017, 99, S30-S31.	0.4	0
123	A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Molecular Cancer Research, 2017, 15, 1764-1776.	1.5	61
124	Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 587-595.	0.9	37
125	Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition. Cells Tissues Organs, 2017, 203, 114-127.	1.3	31
126	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell, 2017, 171, 1284-1300.e21.	13.5	366

#	ARTICLE	IF	CITATIONS
127	High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 191-199.	0.2	4
128	A phase II randomized trial of Observation versus stereotactic ablative Radiatlon for OLigometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , 2017, 17, 453.	1.1	83
129	Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 28-35.	2.0	120
130	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. <i>Nature Reviews Urology</i> , 2017, 14, 15-25.	1.9	210
131	Pelvic Radiation and Normal Tissue Toxicity. <i>Seminars in Radiation Oncology</i> , 2017, 27, 358-369.	1.0	56
132	Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion. <i>Journal of Oncology Practice</i> , 2017, 13, 21-24.	2.5	6
133	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5020-5020.	0.8	2
134	Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 101520-101534.	0.8	8
135	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5094-TPS5094.	0.8	0
136	Abstract 3201: Therapeutic potential of anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma. , 2017, , .		0
137	Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes. <i>Frontiers in Oncology</i> , 2016, 6, 85.	1.3	41
138	Evaluation of On- and Off-Line Bioluminescence Tomography System for Focal Irradiation Guidance. <i>Radiation Research</i> , 2016, 186, 592.	0.7	9
139	PD28-10 COMBINATORIAL THERAPEUTIC APPROACHES WITH PD-1 INHIBITION IN PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
140	MP14-12 EFFICACY OF EARLY AND DELAYED RADIATION IN A PROSTATECTOMY COHORT ADJUSTED FOR GENOMIC AND CLINICAL RISK. <i>Journal of Urology</i> , 2016, 195, .	0.2	1
141	PD42-06 INTERMEDIATE-TERM OUTCOMES IN MEN WITH VERY HIGH RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
142	Concurrent Androgen Deprivation with Radiotherapy: A Cautionary Tale of "Do As I Say, Not As I Do". <i>European Urology</i> , 2016, 70, 436-437.	0.9	0
143	MP09-11 TRENDS IN SURGICAL MANAGEMENT OF HIGH-RISK PROSTATE CANCER: EVIDENCE OF AN EVOLVING TREATMENT PARADIGM. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
144	MP90-08 THE RELATIONSHIP OF B7H3 EXPRESSION TO ANDROGEN AND PROSTATE CANCER OUTCOMES IN A LARGE NATURAL HISTORY COHORT OF MEN UNDERGOING PROSTATECTOMY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0

#	ARTICLE	IF	CITATIONS
145	Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer and Prostatic Diseases, 2016, 19, 277-282.	2.0	23
146	PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer and Prostatic Diseases, 2016, 19, 223-230.	2.0	121
147	Efficacy of Postoperative Radiation in a Prostatectomy Cohort Adjusted for Clinical and Genomic Risk. International Journal of Radiation Oncology Biology Physics, 2016, 96, S103-S104.	0.4	0
148	SNAI1 Regulates the Hexosamine Biosynthesis Pathway to Promote Kras Mutant Lung Tumorigenesis. International Journal of Radiation Oncology Biology Physics, 2016, 96, S54-S55.	0.4	1
149	Stereotactic Ablative Radiation Therapy for the Treatment of Oligometastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E248.	0.4	1
150	RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3. Cancer Research, 2016, 76, 6340-6350.	0.4	56
151	MP07-03 PRIMARY TUMOR ANDROGEN RECEPTOR SIGNALING AS A PREDICTOR OF CASTRATE RESISTANCE. Journal of Urology, 2016, 195, .	0.2	0
152	MP69-12 PREDICTORS OF SURGICAL CURE IN MEN WITH VERY HIGH RISK PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0
153	MP50-18 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN THE EVALUATION OF MEN WITH AN ELEVATED PSA FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2016, 195, .	0.2	1
154	MP23-12 INTRAOPERATIVE RADIATION THERAPY DURING GENITOURINARY SURGERY: THE IMPORTANCE OF SPECIMEN MARGIN STATUS IN IMPROVING SURVIVAL. Journal of Urology, 2016, 195, .	0.2	0
155	Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. , 2016, 4, 28.		52
156	A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2016, 19, 100-106.	2.0	14
157	Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 254-262.	0.4	31
158	Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 571-579.	0.4	172
159	Ganetespib radiosensitization for liver cancer therapy. Cancer Biology and Therapy, 2016, 17, 457-466.	1.5	12
160	Bioluminescence Tomographyâ€“Guided Radiation Therapy for Preclinical Research. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1144-1153.	0.4	44
161	Case volume and improved outcomes across cancer care. Nature Reviews Urology, 2016, 13, 186-187.	1.9	1
162	Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.. Journal of Clinical Oncology, 2016, 34, 12-12.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Effect of local therapy on the systemic anti-tumor response in prostate cancer.. Journal of Clinical Oncology, 2016, 34, 243-243.	0.8	0
164	Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 299-299.	0.8	0
165	Dosimetric predictors of sexual function decline following LDR brachytherapy for prostate cancer (PCa).. Journal of Clinical Oncology, 2016, 34, 113-113.	0.8	0
166	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	0.8	0
167	The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.. Journal of Clinical Oncology, 2016, 34, 256-256.	0.8	1
168	Abstract 1054: SNAIL1 regulates the hexosamine biosynthetic pathway to promote tumorigenesis and oncogene-induced senescence escape in lung cancer. , 2016, , .		0
169	Targeting <sc>DDX</sc>3 with a small molecule inhibitor for lung cancer therapy. EMBO Molecular Medicine, 2015, 7, 648-669.	3.3	189
170	Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Radiation Oncology, 2015, 10, 232.	1.2	13
171	The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 259-265.	0.6	171
172	Structure-Function Studies of the bHLH Phosphorylation Domain of TWIST1 in Prostate Cancer Cells. Neoplasia, 2015, 17, 16-31.	2.3	21
173	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology, 2015, 35, S5-S24.	4.3	231
174	MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6539-6544.	3.3	211
175	Reply to C.G. Rusthoven et al. Journal of Clinical Oncology, 2015, 33, 1990-1991.	0.8	0
176	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
177	End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation for prostate cancer.. Journal of Clinical Oncology, 2015, 33, 68-68.	0.8	1
178	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. Journal of Gastrointestinal Oncology, 2015, 6, 115-25.	0.6	22
179	A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy (RT) in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2015, 33, 35-35.	0.8	0
180	Abstract 21: TWIST1 is required for suppression of apoptosis in oncogene driven non-small cell lung carcinoma. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
181	Abstract 2291: Snai1 accelerates Kras driven lung tumorigenesis by overcoming oncogene-induced senescence. , 2015, , .		0
182	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. <i>Oncology</i> , 2015, 29, 331-40.	0.4	45
183	Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model. <i>PLoS ONE</i> , 2014, 9, e101764.	1.1	206
184	Solitary Plasmacytoma of the Penile Urethra Treated With Primary Radiotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, e95-e97.	0.8	3
185	Low Interrater Reliability in Grading of Rectal Bleeding Using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity Scales: A Survey of Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1076-1082.	0.4	11
186	Adjuvant Radiation for Node-Positive Disease After Prostatectomy: More Good News, but Who Will Listen?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3917-3919.	0.8	5
187	Twist1-induced dissemination preserves epithelial identity and requires E-cadherin. <i>Journal of Cell Biology</i> , 2014, 204, 839-856.	2.3	178
188	Epigenetic inactivation of DNA repair in breast cancer. <i>Cancer Letters</i> , 2014, 342, 213-222.	3.2	27
189	MP46-06 SELECTION CRITERIA FOR EARLY BIOCHEMICAL RECURRENCE IN A HIGH-RISK RADICAL PROSTATECTOMY COHORT. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
190	Î±5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. <i>Acta Neuropathologica</i> , 2014, 127, 593-603.	3.9	39
191	Identification of men with the highest risk of early disease recurrence after radical prostatectomy. <i>Prostate</i> , 2014, 74, 628-636.	1.2	24
192	Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6406-6417.	3.2	47
193	Multiple Intermediate-Risk Factors as a Prognostic Tool for Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S454.	0.4	0
194	A Twist1-MLL-WDR5-HOTTIP Complex Regulates HOXA9 Chromatin to Facilitate Metastasis of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S177.	0.4	5
195	Abstract A12: Screening for TWIST1 inhibitors as a novel therapy for oncogene-driven lung cancer.. <i>Clinical Cancer Research</i> , 2014, 20, A12-A12.	3.2	1
196	Baseline Hemoglobin-A1c Impacts Clinical Outcomes in Patients With Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 50-57.	2.3	16
197	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 269-269.	0.8	15
198	Twist1 induces dissemination by activating an epithelial motility program that requires E-cadherin (LB230). <i>FASEB Journal</i> , 2014, 28, LB230.	0.2	0

#	ARTICLE	IF	CITATIONS
199	Abstract 4771: Identification of inhibitors of TWIST1 as a treatment for lung cancer. , 2014, , .		0
200	Abstract 3405: E12 and E47 are essential for TWIST1 dependent suppression of oncogene-induced senescence in NSCLC. , 2014, , .		0
201	Mapping Patterns of Local Recurrence After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A New Approach to Adjuvant Radiation Field Design. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1007-1015.	0.4	63
202	Immune Checkpoint Upregulation Following Radiation Therapy: Rationale for Combining Radiation Therapy With Multiple Immune Checkpoint Blockades. International Journal of Radiation Oncology Biology Physics, 2013, 87, S109-S110.	0.4	0
203	Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas. International Journal of Radiation Oncology Biology Physics, 2013, 86, 343-349.	0.4	757
204	Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: A dosimetric analysis. Medical Dosimetry, 2013, 38, 243-250.	0.4	13
205	Primary squamous cell carcinoma of the vagina: Prognostic factors, treatment patterns, and outcomes. Gynecologic Oncology, 2013, 131, 380-385.	0.6	78
206	Radiosensitizers in pancreatic cancer—Preclinical and clinical exploits with molecularly targeted agents. Current Problems in Cancer, 2013, 37, 301-312.	1.0	1
207	Hedgehog Pathway Inhibition Radiosensitizes Non-Small Cell Lung Cancers. International Journal of Radiation Oncology Biology Physics, 2013, 86, 143-149.	0.4	37
208	Twist1 Induces the Step-Wise Malignant Progression of Liver Cancer in Transgenic Mice Revealing a Prognostic 19-Gene Signature for Humans. International Journal of Radiation Oncology Biology Physics, 2013, 87, S169.	0.4	0
209	The Twist Box Domain Is Required for Twist1-induced Prostate Cancer Metastasis. Molecular Cancer Research, 2013, 11, 1387-1400.	1.5	79
210	Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 14800-14832.	1.8	34
211	Practice-Based Evidence to Evidence-Based Practice: Building the National Radiation Oncology Registry. Journal of Oncology Practice, 2013, 9, e90-e95.	2.5	29
212	Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results. Journal of Clinical Oncology, 2013, 31, 886-894.	0.8	173
213	Inhibition of TWIST1 Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non-Small Cell Lung Cancer. Molecular Cancer Research, 2013, 11, 329-338.	1.5	54
214	Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses. BioMed Research International, 2013, 2013, 1-8.	0.9	66
215	Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biology and Therapy, 2013, 14, 347-356.	1.5	43
216	Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e65726.	1.1	35

#	ARTICLE	IF	CITATIONS
217	Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 343-51.	0.6	55
218	Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 269-269.	0.8	1
219	Abstract B45: The Twist box domain is required for Twist1-induced metastasis of prostate cancer cells. , 2013, , .		0
220	Abstract C39: Building a novel molecular model for Twist1-induced epithelial dissemination. , 2013, , .		0
221	Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis. <i>PLoS Genetics</i> , 2012, 8, e1002650.	1.5	86
222	Tissue Biomarkers for Prostate Cancer Radiation Therapy. <i>Current Molecular Medicine</i> , 2012, 12, 772-787.	0.6	19
223	Orthovoltage Intraoperative Radiotherapy for Locally Advanced and Recurrent Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 695-702.	0.7	12
224	Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 231-237.	0.4	66
225	Concurrent Versus Sequential Sorafenib Therapy in Combination With Radiation for Hepatocellular Carcinoma: A Preclinical Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S337.	0.4	0
226	Novel Hsp90 Inhibitor NVP-AUY922 Radiosensitizes Prostate Cancer Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S178.	0.4	1
227	Utility of Daily Cone Beam CT in Predicting Setup Within Clinical CTV-PTV Margins in Lung Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S594.	0.4	0
228	Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease. <i>Radiation Oncology</i> , 2012, 7, 5.	1.2	42
229	Effect of chemoradiation-related lymphopenia on survival in patients with unresectable, locally advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 307-307.	0.8	0
230	Abstract 2954: TWIST1 is a critical mediator of KRAS mutant tumorigenesis in human non-small cell lung cancer. , 2012, , .		0
231	Abstract 2975: Transgenic mouse model of Twist1-induced metastasis reveals genes highly prognostic for human hepatocellular carcinoma. , 2012, , .		0
232	Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation. <i>Science Translational Medicine</i> , 2011, 3, 103ra99.	5.8	38
233	Combining Anti-PD-1 (B7-H1) Immunotherapy with Stereotactic Radiosurgery in a Mouse Orthotopic Glioblastoma Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S82-S83.	0.4	0
234	Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series. <i>Radiation Oncology</i> , 2011, 6, 25.	1.2	8

#	ARTICLE	IF	CITATIONS
235	Nelfinavir induces radiation sensitization in pituitary adenoma cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 657-663.	1.5	25
236	Development of a Micro-Computed Tomography-Based Image-Guided Conformal Radiotherapy System for Small Animals. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 297-305.	0.4	67
237	Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S546-S547.	0.4	0
238	Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. <i>Radiation Oncology</i> , 2010, 5, 105.	1.2	7
239	Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics. <i>Clinical Cancer Research</i> , 2010, 16, 4843-4852.	3.2	81
240	PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel ⁶⁴ Cu-DOTA-Knottin Peptide. <i>Cancer Research</i> , 2010, 70, 9022-9030.	0.4	43
241	External Beam Radiation Therapy Enhances Local Control in Pigmented Villonodular Synovitis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 183-187.	0.4	57
242	Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1587-1589.	0.5	5
243	CYBERKNIFE FOR BRAIN METASTASES OF MALIGNANT MELANOMA AND RENAL CELL CARCINOMA. <i>Neurosurgery</i> , 2009, 64, A26-A32.	0.6	56
244	SU-FF-J-162: In Vivo Biological Evaluation of Micro-CT Based 3D Conformal Radiotherapy System. <i>Medical Physics</i> , 2009, 36, 2514-2514.	1.6	0
245	MYC Potentiates DNA Damage Response Dependent Cellular Senescence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S693.	0.4	0
246	Intraoperative Radiation Therapy for Locally Advanced and Recurrent Soft-Tissue Sarcomas in Adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1146-1153.	0.4	20
247	The current state of biomarkers to predict the response to anti-Angiogenic therapies. <i>Cancer Biology and Therapy</i> , 2008, 7, 2004-2006.	1.5	2
248	Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas. <i>PLoS ONE</i> , 2008, 3, e2125.	1.1	74
249	Long-Term Survivors Using Intraoperative Radiotherapy for Recurrent Gynecologic Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 504-511.	0.4	56
250	Predictive Modeling of Tumor Regression Kinetics Using a Murine Model of Oncogene-Addicted Lung Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S596-S597.	0.4	0
251	A mutation in EXO1 defines separable roles in DNA mismatch repair and post-replication repair. <i>DNA Repair</i> , 2007, 6, 1572-1583.	1.3	49
252	Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. <i>Gynecologic Oncology</i> , 2007, 105, 641-649.	0.6	50

#	ARTICLE	IF	CITATIONS
253	2766. International Journal of Radiation Oncology Biology Physics, 2006, 66, S638-S639.	0.4	0
254	2119. International Journal of Radiation Oncology Biology Physics, 2006, 66, S276.	0.4	2
255	Postmortem molecular screening in unexplained sudden death. Journal of the American College of Cardiology, 2004, 43, 1625-1629.	1.2	149
256	EXO1-A multi-tasking eukaryotic nuclease. DNA Repair, 2004, 3, 1549-1559.	1.3	176
257	Characterization of nuclease-dependent functions of Exo1p in Saccharomyces cerevisiae. DNA Repair, 2002, 1, 895-912.	1.3	113
258	Alleles of the Yeast PMS1 Mismatch-Repair Gene That Differentially Affect Recombination- and Replication-Related Processes. Genetics, 2002, 162, 1131-1145.	1.2	28
259	MSH-MLH complexes formed at a DNA mismatch are disrupted by the PCNA sliding clamp. Journal of Molecular Biology, 2001, 306, 957-968.	2.0	71
260	Interactions of Exo1p with components of MutL Δ in Saccharomyces cerevisiae. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9760-9765.	3.3	114
261	Functional Studies on the Candidate ATPase Domains of Saccharomyces cerevisiae MutL Δ . Molecular and Cellular Biology, 2000, 20, 6390-6398.	1.1	91
262	Analysis of yeast MSH2-MSH6 suggests that the initiation of mismatch repair can be separated into discrete steps 1 Edited by M. Gottesman. Journal of Molecular Biology, 2000, 302, 327-338.	2.0	40
263	Functional Studies on the Candidate ATPase Domains of Saccharomyces cerevisiae MutL Δ . Molecular and Cellular Biology, 2000, 20, 6390-6398.	1.1	5
264	Molecular cloning of the human methylthioadenosine phosphorylase processed pseudogene and localization to 3q28. Gene, 1997, 186, 263-269.	1.0	8
265	Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 6203-6208.	3.3	99